Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma

Oncologist

Volumn 23, Issue 1, 2018, Pages 118-120

  Papadopoulos, Kyriakos P ^a   Romero, Rebecca S ^b   Gonzalez, Gabriela ^b   Dix, James E ^c   Lowy, Israel ^d   Fury, Matthew ^d  

^a South Texas Accelerated Research Therapeutics   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c South Texas Radiology Group   (United States)

^d Regeneron Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; CD68 ANTIGEN; CEMIPLIMAB; ELAV PROTEIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; REGN 2810; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

ADULT; ALLERGIC ENCEPHALITIS; ANXIETY; ARTICLE; AUTOPSY; BRAIN RADIOGRAPHY; BRONCHOPNEUMONIA; CASE REPORT; CEREBROSPINAL FLUID; CHONDROSARCOMA; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEPRESSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSARTHRIA; FLUORESCENCE IN SITU HYBRIDIZATION; HOSPICE CARE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS RESECTION; MIDDLE AGED; MYXOSARCOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; PATIENT HISTORY OF TUMORECTOMY; PLEOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; THROMBOEMBOLISM; WEAKNESS; WESTERN BLOTTING; AUTOIMMUNE DISEASE; FATALITY; IMMUNOLOGY; PATHOLOGY; SOFT TISSUE TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; CHONDROSARCOMA; ELAV PROTEINS; FATAL OUTCOME; HUMANS; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; NEOPLASMS, CONNECTIVE AND SOFT TISSUE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85040316305     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2017-0344     Document Type: Article

References (13)

1. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.
2. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–1982.
3. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806–812.
4. Graus F, Keime-Guibert F, Reñe R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 2001;124:1138–1148.
5. Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992;71:59–72.
6. Antonia SJ, López-Martin JA, Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883–895.
7. Williams TJ, Benavides DR, Patrice KA et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933.
8. Gultekin SH, Rosenfeld MR, Voltz R et al. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481–1494.
9. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993;341:21–22.
10. Hoosien M, Vredenburgh J, Lanfranco J et al. A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis. J Neurooncol 2011;101:135–139.
11. Verschuuren J, Twijnstra A, De Baets M et al. Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma. Neurology 1994;44:1551–1552.
12. Bien CG, Vincent A, Barnett MH et al. Immunopathology of autoantibody-associated encephalitides: Clues for pathogenesis. Brain 2012;135:1622–1638.
13. McGranahan N, Furness AJ, Rosenthal R et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016;351:1463–1469.